SciClone Pharmaceuticals, Inc.(NASDAQ : SCLN)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||0.04%||172.25||0.7%||$1088.53m|
|MRK||Merck & Co., Inc.||-0.13%||76.83||0.7%||$651.89m|
|BMY||Bristol-Myers Squibb Co.||-0.34%||67.92||1.0%||$580.36m|
|LLY||Eli Lilly & Co.||-0.80%||243.36||1.1%||$577.91m|
|NRXP||NRX Pharmaceuticals, Inc.||0.20%||15.18||0.0%||$167.78m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||-0.06%||126.06||0.0%||$85.37m|
|NVO||Novo Nordisk A/S||1.32%||92.58||0.1%||$81.36m|
|RPRX||Royalty Pharma Plc||-0.13%||38.20||0.2%||$73.90m|
SciClone Pharmaceuticals, Inc. (SciClone ) is a global specialty pharmaceutical company. It has a product portfolio of therapies for cancer and infectious diseases. SciClone has in-licensed two products that are part of this international commercial growth strategy, DC Bead and ondansetron RapidFilm. Its DC Bead product candidate is a treatment for liver cancer, which is approved in 40 countries worldwide, including Europe and the United States. Ondansetron RapidFilm is an oral thin film formulation of ondansetron used to treat and prevent nausea and vomiting caused by chemotherapy, radiotherapy and surgery. SCV-07 is being developed for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck and for the treatment of hepatitis C virus (HCV). Thymalfasin is being developed in an ongoing clinical trial for improvement of Influenza A (H1N1) vaccination.